STANDARD BIOTOOLS INC.

Listed Company

LABCIK 0001162194NasdaqAcceleratedLaboratory Analytical InstrumentsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$85.33M

Net Income

$-74.90M

Total Assets

$567.75M

Equity

$424.29M

Shares Out

390.14M

Op. Cash Flow

$-74.34M

LAB$0.91−26.92% · past yearDBEQ Basic

Daily closing prices

Business

Standard BioTools Inc. is a life science tools company that provides instrumentation, consumables, and services for biomedical research across proteomics and genomics. The company offers three core platforms: CyTOF (mass cytometry for single-cell analysis), Hyperion (spatial biology imaging), and Biomark (high-throughput genomics via microfluidics). Standard BioTools serves academic research institutions, translational research centers, and biopharmaceutical companies through direct sales and distribution in North America, Europe, and Asia-Pacific, with manufacturing operations in Singapore and Canada.

Summary from 10-K filed 2026-03-16

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	85	91	106	98	131
Total cost of revenue	43	46	56	61	—
Gross profit	43	45	50	37	—
Research and development	26	29	26	37	38
Selling, general and administrative	110	103	88	102	99
Restructuring and related charges	15	13	7	10	—
Transaction and integration expenses	2	28	6	4	—
Total operating expenses	153	172	127	153	198
Loss from continuing operations	−110	−127	−77	−116	−67
Bargain purchase gain	0	25	0	0	—
Interest income	9	20	6	2	—
Interest expense	−26,000	−3	−5	−4	—
Other income (expense), net	4	−5	1	−818,000	482,000
Loss before income taxes	−97	−90	−74	−193	−64
Income tax benefit (expense)	38	−542,000	−452,000	3	4
Net loss from continuing operations	−59	−91	−75	—	—
Loss from discontinued operations, net of tax	−16	−48	0	—	—
Net loss	−75	−139	−75	−190	−59
Less: Induced conversion of redeemable preferred stock	0	−46	0	0	—
Net loss attributable to common stockholders	−75	−185	−75	−190	—
Net loss per share from continuing operations, basic (in dollars per share)	−0.15	−0.39	−0.94	—	—
Net loss per share from continuing operations, diluted (in dollars per share)	−0.15	−0.39	−0.94	—	—
Net loss per share from discontinued operations, basic (in dollars per share)	−0.04	−0.14	0	—	—
Net loss per share from discontinued operations, diluted (in dollars per share)	−0.04	−0.14	0	—	—
Net loss per share attributable to common stockholders, basic (in dollars per share)	−0.2	−0.52	−0.94	−2.43	−0.78
Net loss per share attributable to common stockholders, diluted (in dollars per share)	−0.2	−0.52	−0.94	−2.43	−0.78
Shares used in computing net loss per share attributable to common stockholders, basic (in shares)	382	353	79	78	76
Shares used in computing net loss per share attributable to common stockholders, diluted (in shares)	382	353	79	78	76

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	121	167	52	81	28
Short-term investments	67	126	63	84	0
Accounts receivable, net	13	15	20	17	18
Inventory	20	21	21	21	21
Prepaid expenses and other current assets	5	5	3	4	4
Current assets held for sale	228	43	—	—	—
Total current assets	454	376	158	209	72
Property and equipment, net	19	23	24	26	28
Operating lease right-of-use asset, net	27	27	31	34	37
Other non-current assets	3	4	2	3	4
Long-term investments	26	0	—	—	—
Deferred tax asset, non-current	39	138,000	—	—	—
Non-current assets held for sale	0	183	—	—	—
Total assets	568	612	323	390	275
Accounts payable	5	5	9	8	11
Accrued liabilities	30	21	21	6	9
Operating lease liabilities, current	5	5	4	4	3
Deferred revenue, current	39	10	12	11	12
Deferred grant income, current	3	4	4	4	4
Current liabilities held for sale	26	21	—	—	—
Total current liabilities	108	66	109	43	50
Convertible notes, non-current	299,000	299,000	569,000	55	—
Deferred tax liability	810,000	1	841,000	1	4
Operating lease liabilities, non-current	25	26	30	34	38
Deferred revenue, non-current	4	33	4	4	6
Deferred grant income, non-current	4	7	11	—	—
Other non-current liabilities	1	1	1	961,000	882,000
Non-current liabilities held for sale	—	7	—	—	—
Total liabilities	143	141	160	161	181
Commitments and contingencies (Note 8)	—	—	—	—	—
Common stock: $0.001 par value, 600,000 shares authorized at December 31, 2025 and 2024; 404,961 and 396,110 shares issued at December 31, 2025 and 2024, respectively; 386,381 and 377,530 shares outstanding at December 31, 2025 and 2024, respectively	404,000	396,000	83,000	80,000	77,000
Additional paid-in capital	1,732	1,702	861	847	831
Accumulated other comprehensive income (loss)	−1	1	−2	−2	−907,000
Accumulated deficit	−1,261	−1,186	−1,001	−926	−736
Treasury stock at cost: 18,580 shares at December 31, 2025 and 2024	−46	−46	−6	−563,000	0
Total stockholders' equity	424	472	−148	−81	95
Total liabilities and stockholders' equity	568	612	323	390	275

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Stock-based compensation expense	30	32	13	15	16
Amortization of acquired intangible assets	2	4	11	12	12
Depreciation and amortization	9	13	4	3	4
Accretion of discount on short-term investments, net	−3	−7	−1	−674,000	—
Unrealized loss on equity investments	602,000	0	0	—	—
Non-cash lease expense	6	6	4	4	—
Provision for excess and obsolete inventory	3	3	1	8	2
Change in fair value of warrants	−232,000	−632,000	0	—	—
Change in fair value of contingent consideration	−3	0	0	—	—
Other non-cash items	905,000	1	939,000	1	520,000
Accounts receivable, net	−1	9	−3	1	7
Inventory	−12	−10	−5	−8	−5
Prepaid expenses and other assets	1	−2	862,000	33,000	−436,000
Deferred tax asset, non-current	−38	−6,000	98,000	—	—
Accounts payable	2	−13	2	−3	1
Accrued liabilities	10	815,000	6	4	—
Deferred revenue	−1	−4	884,000	−3	−3
Operating lease liabilities	−6	−6	−4	−3	—
Other liabilities	−208,000	−4	47,000	−6	−11
Net cash used in operating activities	−74	−143	−43	−89	−44
Cash and restricted cash acquired in the Merger	0	280	0	—	—
Acquisition of business, net of cash acquired	0	−1	0	—	0
Purchases of short-term marketable debt securities	−99	−256	−95	—	—
Purchases of long-term marketable debt securities	−32	0	0	—	—
Purchases of marketable equity securities	−7	0	0	—	—
Purchase of convertible note receivable	−5	0	0	—	—
Proceeds from sales and maturities of investments	179	349	118	53	0
Purchases of property and equipment	−8	−8	−3	−4	−13
Net cash provided by investing activities	27	363	20	−88	−12
Repayment of term loan and convertible notes	0	−63	−2	−7	0
Payment of term loan fee	0	−545,000	0	—	—
Repurchase of common stock	0	−40	−5	−563,000	0
Proceeds from ESPP stock issuance	523,000	918,000	723,000	820,000	1
Payments for taxes related to net share settlement of equity awards and other	−484,000	−459,000	−139,000	−211,000	−2
Proceeds from exercise of stock options	531,000	1	104,000	97,000	209,000
Net cash provided by (used in) financing activities	570,000	−103	−7	231	16
Effect of foreign exchange rate fluctuations on cash and cash equivalents	842,000	−785,000	34,000	−404,000	−21,000
Net increase (decrease) in cash, cash equivalents and restricted cash	−46	116	−30	53	−40
Equity consideration transferred in connection with business combinations	0	450	0	—	—
Cash paid for interest	15,000	3	4	3	3
(Cash paid) cash refund received for income taxes	−73,000	607,000	801,000	309,000	2
Purchases of property and equipment included in accounts payable	851,000	2	0	4	—
Non-cash right-of-use assets and lease liabilities	5	220,000	629,000	651,000	−2
Asset retirement obligations	657,000	788,000	758,000	718,000	710,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is STANDARD BIOTOOLS INC.'s CIK number?

STANDARD BIOTOOLS INC.'s SEC CIK number is 0001162194 (1162194). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find STANDARD BIOTOOLS INC.'s SEC filings?

All of STANDARD BIOTOOLS INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did STANDARD BIOTOOLS INC. last report earnings?

STANDARD BIOTOOLS INC. (LAB) most recently filed an earnings 8-K with the SEC on May 5, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-206395). This is STANDARD BIOTOOLS INC.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is STANDARD BIOTOOLS INC.'s most recent earnings 8-K?

STANDARD BIOTOOLS INC.'s latest earnings 8-K (Item 2.02) was filed May 5, 2026 under accession 0001193125-26-206395. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View STANDARD BIOTOOLS INC.'s latest earnings 8-K →
Look up any company's CIK number →